CSPIA
KRON

Cary Street Partners Investment Advisory’s Kronos Bio KRON Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,000
Closed -$2.6K – 1281
2023
Q3 		$2.6K Hold
2,000
– – ﹤0.01% 1618
2023
Q2 		$3.44K Hold
2,000
– – ﹤0.01% 1497
2023
Q1 		$2.92K Buy
+2,000
New +$3.83K ﹤0.01% 1443

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cary Street Partners Investment Advisory's KRON Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Kronos Bio (KRON) in Q4 2023, closing a stake of 2,000 shares — an estimated $2.6K sold.

Cary Street Partners Investment Advisory first reported a position in KRON in Q1 2023 and held it in 3 quarters. The position peaked at $3.44K in Q2 2023. 60 funds tracked by Wall St. Rank hold KRON as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Kronos Bio position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 2,000 Kronos Bio shares in Q4 2023, an estimated $2.6K.
  • Cary Street Partners Investment Advisory first reported a position in Kronos Bio in Q1 2023 and held it in 3 quarters.
  • Cary Street Partners Investment Advisory's Kronos Bio position peaked at $3.44K in Q2 2023.
  • 60 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.